MyFinsight
Home
Blog
About
Proceeds from
convertible notes, net
$2,163,600
Proceeds from share
purchases under eloc, net...
$700,491
(-71.12%↓ Y/Y)
Net cash provided by
financing activities
$2,407,925
(-73.38%↓ Y/Y)
something is missing
$1,956,166
Canceled cashflow
$456,166
Net decrease in
cash, restricted cash...
-$724,868
Canceled cashflow
$4,364,091
Loss on initial and
revaluation of derivative...
-$4,000,255
Stock-based compensation
$2,739,540
(461.07%↑ Y/Y)
Amortization of debt discount
$609,882
Accounts payable
$530,041
(-5.67%↓ Y/Y)
Amortization of right-to-use
operating lease asset
$434,632
(11.04%↑ Y/Y)
Prepaid expenses and
other current assets
-$106,471
(-162.95%↓ Y/Y)
something is missing
-$456,166
Net cash used in
operating activities
-$5,088,959
(43.88%↑ Y/Y)
Canceled cashflow
$8,420,821
Gain on revaluation
of preferred stock...
-$6,610,240
something is missing
-$5,336,134
Net loss
-$1,028,830
(90.22%↑ Y/Y)
Operating lease liability
-$243,272
(42.47%↑ Y/Y)
Insurance financing
liability
-$180,536
Depreciation expense
-$94,868
(-165.11%↓ Y/Y)
Accrued liabilities
-$15,779
(96.10%↑ Y/Y)
Foreign currency
transaction gain included in...
$121
Back
Back
Cash Flow
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
source: myfinsight.com